Biocon Looks To Margin Expansion Ahead

After integrating its biologics business and raising nearly $1 billion through two equity issuances, Biocon is positioning for improved profitability. Lower interest costs and operating leverage are expected to support margins as the company scales its biosimilars and generics businesses.